Cerenome is trading 24.29% down at $0.68, with no fresh company-specific catalyst identified for November 5, 2026.
- The November 4 Aetna agreement expanded contracted coverage by about 26 million members to approximately 190 million lives; shares fell after the announcement.
- Broader sentiment was sharply negative, with the S&P 500 down 2.20% and Nasdaq down 3.70%; this risk-off backdrop may be contributing, though no source directly links it to Cerenome’s decline.